Vers une réduction du risque de rechute des patientes présentant un cancer du sein localisé surexprimant HER2 ? (notice n° 271783)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02227cam a2200337 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112080957.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Reverdy, Thibaut |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Vers une réduction du risque de rechute des patientes présentant un cancer du sein localisé surexprimant HER2 ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 96 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméLe traitement des cancers du sein localisés surexprimant HER2 est en pleine transformation. Si le trastuzumab a amélioré le pronostic de ces patientes, près de 30 % présenteront une récidive dans les 11 ans. Ce taux important incite à optimiser le blocage de la voie HER2 dès le stade précoce. Les traitements ciblant HER2 avec un impact favorable aux stades précoces et métastatiques ont été évalués dans des essais de phases II et III.. Ils ont montré une supériorité en taux de réponse ou en survie sans récidive par rapport à un traitement par trastuzumab seul. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The treatment of HER2-overexpressing localized breast cancer is undergoing significant transformation. While trastuzumab has significantly improved the prognosis for these patients, almost 30% will have a relapse within 11 years. With such a high recurrence rate, optimization of HER2 pathway inhibition at an early stage is mandatory. HER2-targeted therapies with a favourable impact at the metastatic stage have been evaluated in Phase II and III trials, and have demonstrated superiority regarding complete response rate or disease-free survival, compared to a treatment with trastuzumab alone. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | survie sans maladie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HER2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du sein au stade précoce |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pCR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | survie globale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | stratégie thérapeutique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | + |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | overall survival |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | early-stage breast cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | therapeutic strategy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | HER2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pCR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | + |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | disease-free survival |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 7 | 2 | 2021-03-01 | p. 101-108 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2021-2-page-101?lang=fr">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2021-2-page-101?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux